Explanation:
None of these conditions are considered IBD. Though they have similar names, IBD is different from irritable bowel syndrome (IBS). Unlike IBD, IBS does not cause inflammation, ulcers, or other damage to the bowel. With IBS, the digestive system looks normal but does not function like it should. Symptoms of IBS include cramps, bloating, mucus in the stool, diarrhea, and constipation. Celiac disease is an autoimmune disease where the ingestion of gluten leads to damage to the small intestine, and GERD occurs when stomach acid frequently flows back into the esophagus.
Explanation:
In Crohn’s disease, inflammation can begin anywhere in the gastrointestinal tract (from the mouth to the anus), and all layers of the bowel walls may be inflamed so patients often experience more severe abdominal pain. However, with UC, inflammation affects only the inner lining of the colon, and the affected area begins at or near the rectum. Due to these differences, bloody stools are more common in individuals with UC compared to those with Crohn’s disease.
Explanation:
The incidence of inflammatory bowel disease is lower in developing countries than in developed countries, but there is evidence of an increase in recent decades in developing countries that have undergone industrialization.
Explanation: A continent ileostomy is a procedure where an intra-abdominal reservoir is created and a nipple valve is attached to prevent drainage of stool from the reservoir. A nipple valve is not used during an ileostomy, loop ostomy, or temporary ostomy.
Explanation:
IBD is actually most common in the United States and Europe, with approximately 3.6 million people living with the disease (1.4 million and 2.2 million in each region, respectively). IBD has an increased rate of diagnosis in adults between 15 and 35 years old. The number of people being diagnosed with IBD has also been rising, which may be due in part to better detection and diagnosis.
Explanation:
IBD is known for its complicated and unpredictable nature. During periods of good health, people with IBD may feel strong and well. However, IBD symptoms can flare up at any time, often for prolonged periods. During these periods, individuals with IBD can experience a variety of disruptive symptoms from frequent bowel movements and abdominal pain to even hospitalizations and surgeries.
Explanation:
It is estimated there are trillions of microorganisms in our gut, which may weigh as much as five pounds! Our body is home to a vast ecosystem of microorganisms, and their combined genetic material, containing millions of genes, is known as the microbiome. Read more about the work we are doing to understand the role the microbiome might play in IBD here.
Explanation:
A systematic review of the effectiveness of azathioprine in maintaining remission of quiescent Crohn’s disease identified five randomized controlled trials. The drug had a positive effect on maintaining remission.
Explanation:
There is no cure for IBD. As doctors do not yet fully understand what causes the disease, people with IBD may feel concerned, confused, and anxious about their future. Treatment goals for IBD are evolving, but there is a significant need for new treatment options that address the challenges and are effective, safe, and convenient.
Explanation:
Inflammation in IBD is caused by an increased number of white blood cells. In people without IBD, white blood cells are able to attack and remove foreign cells from the gut. In patients with IBD, there is an increased number of white blood cells present which triggers an exaggerated immune response in the gut, and damage is caused through excessive and continuous inflammation.
Explanation:
It’s estimated that about 80% of people with moderate to severe IBD do not experience long-term remission. Treatment goals focused on healing inflammation and ulceration in the gut may better predict long-term health.
